New insights into the genetic basis of premature ovarian insufficiency: Novel causative variants and candidate genes revealed by genomic sequencing
Introduction
Women are born with their future oocyte supply, which is established during development and reaches its maximum size of ∼5 million germ cells around 20 weeks of gestation. After this peak, there is a steady atresia of oocytes with ∼1−2 million by birth, further depleted to about half a million by menarche [1,2]. After menarche, women lose an average of 1000 oocytes per month, one of which completes maturation and is ovulated as part of the menstrual cycle [3]. The number of oocytes within each woman, corresponding to the ovarian reserve, is variable [4]. The cyclic oocyte maturation and loss of ovarian reserve occurs until menopause at an average age of 51 in the western world.
Ovarian deficiency, including premature ovarian insufficiency (POI) and diminished ovarian reserve (DOR), is one of the main causes of female infertility. A DOR is mostly the consequence of age but is considered abnormal if it occurs before the age of 40 (10 % of women) [4]. In contrast, premature ovarian insufficiency (POI) is characterized by perturbation or cessation of the menstrual cycle along with elevated gonadotropins before the age of 40, affecting as many as 1 in 100 women. There is no evidence that DOR is a precursor of POI and women under 40 can have a DOR without POI. Nevertheless, these conditions are likely manifestations along a continuum of ovarian deficiency with different severity of decrease in ovarian reserve. POI can be devastating for affected women who face infertility, as well as an increased risk of co-morbidities such as cardiovascular disease, mental health problems, osteoporosis and earlier mortality [5,6]. The cause of POI is manifold. It can be secondary to medical interventions or can occur as part of autoimmune conditions, metabolic conditions or genetic syndromes. There is a tendency for affected individuals to have affected family members, indicating the role of inheritance in the condition [7,8]. The genetic basis of POI is further demonstrated by the discovery of causative variants in over 50 different genes [6]. These genes have diverse roles including metabolism, folliculogenesis, gonadogenesis, oogenesis, DNA damage repair, apoptosis, hormone signaling, autoimmunity and more. Current understanding of the genetic basis of POI, however, is far from complete, with the cause remaining unknown in the majority of patients, particularly those with sporadic and isolated POI. Key regulating genes of DOR have also been reported [9] but the genetic basis of DOR has not been explored in depth. Importantly, overlapping genetic background has been reported for POI and DOR [10] providing rationale for testing both conditions using similar methods.
In this study, we have used whole-exome sequencing (WES) followed by thorough variant curation and functional validation to investigate the genetic cause of POI and DOR in a small cohort of 10 patients. All patients had isolated POI or DOR with no related medical history, and were initially analysed as singletons. We were able to provide likely genetic diagnoses to three patients who harboured novel variants in the known POI-related genes STAG3, GDF9, and FANCM. Another patient had variants of uncertain significance with high clinical relevance in FSHR. We also propose the potential involvement of variants in NRIP1, XPO1, and MACF1, three genes known to have a role in ovarian biology but never before associated with human POI.
Section snippets
Ethical adherence and participants
Written informed consent was obtained from all participants. All procedures were in accordance with the ethical standards of the Ethics Committee of Rennes University Hospital and the French law (favourable opinion from the CCTIRS - Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé - for the study).
Patients were recruited for the study after clinical consultation. They were all of Caucasian origin. All patients underwent cytogenetic
Results
We analysed the exome of ten patients with isolated POI or DOR. A summary of patient phenotype is shown in Table 1 and a summary of prioritized variants is provided in supplementary material (Supplementary File 2). Nomenclature validation was performed using Variant Validator https://variantvalidator.org/.
Discussion
In this study, we have used WES to investigate the genetic cause of POI in a small cohort of 10 French women. The first analysis focused on 492 POI diagnostic or candidate genes selected from public databases and from literature data. We were successful in identifying the likely genetic cause for three patients, with novel variants in STAG3, GDF9, and FANCM. One additional patient had variants of uncertain significance with high clinical relevance in a validated POI gene, FSHR. These novel
Contributors
Sylvie Jaillard conceived and designed the study, acquired the data, analyzed and interpreted the data, and wrote the manuscript.
Katrina Bell analyzed and interpreted the data.
Linda Akloul was involved in patient care and evaluation.
Kelly Walton was involved in the functional studies.
Kenneth McElreavy analyzed and interpreted the data.
William A. Stocker was involved in the functional studies.
Marion Beaumont managed the cytogenetic analysis.
Craig Harrisson was involved in the functional studies.
Conflict of Interest
The authors declare no conflicts of interest.
Funding
This work was supported by CHU Rennes and Rennes 1 University, Faculty of Medicine in France, a Peter Doherty Early Career Fellowship(1054432; to E.J.T.), a National Health and Medical Research Council program grant (1074258; to A.H.S.), a fellowship (1062854; to A.H.S.) from the Australian National Health and Medical Research Council, the Sigrid Jusélius Foundation (JJP), and the Victorian Government’s Operational Infrastructure Support Program. WAS was supported by an Australian Government
Ethical approval
All procedures were in accordance with the ethical standards of the Ethics Committee of Rennes University Hospital and the French law (favourable opinion from the CCTIRS Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé for the study).
Research data (data sharing and collaboration)
There are no linked research data sets for this paper. Data will be made available on request.
Provenance and peer review
This article has undergone peer review.
Acknowledgement
We would like to thank all the patients and families for taking part in our research.
References (62)
- et al.
Establishment of ovarian reserve: a quantitative morphometric study of the developing human ovary
Fertil. Steril.
(2007) - et al.
Mothers and daughters menopausal ages: is there a link?
Eur. J. Obstet. Gynecol. Reprod. Biol.
(1997) - et al.
Analysis of NR5A1 in 142 patients with premature ovarian insufficiency, diminished ovarian reserve, or unexplained infertility
Maturitas
(2020) - et al.
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Genet. Med. Off. J. Am. Coll. Med. Genet.
(2015) - et al.
Cumulin, an oocyte-secreted heterodimer of the transforming growth factor-β family, is a potent activator of granulosa cells and improves oocyte quality
J. Biol. Chem.
(2015) - et al.
SUMOylation modulates the transcription repressor function of RIP140
J. Biol. Chem.
(2008) - et al.
Molecular aspects and clinical relevance of GDF9 and BMP15 in ovarian function
Vitam. Horm.
(2018) - et al.
Bi-allelic recessive loss-of-function variants in FANCM cause non-obstructive azoospermia
Am. J. Hum. Genet.
(2018) - et al.
A homozygous FANCM frameshift pathogenic variant causes male infertility
Genet. Med. Off. J. Am. Coll. Med. Genet.
(2019) - et al.
Novel inactivating mutations in the FSH receptor cause premature ovarian insufficiency with resistant ovary syndrome
Reprod. Biomed. Online
(2019)
Receptor interacting protein RIP140 inhibits both positive and negative gene regulation by glucocorticoids
J. Biol. Chem.
Characterization of receptor-interacting protein 140 in retinoid receptor activities
J. Biol. Chem.
Atomic basis of CRM1-cargo recognition, release and inhibition
Semin. Cancer Biol.
MACF1 mutations encoding highly conserved zinc-binding residues of the GAR domain cause defects in neuronal migration and axon guidance
Am. J. Hum. Genet.
ATG7 and ATG9A loss-of-function variants trigger autophagy impairment and ovarian failure
Genet. Med. Off. J. Am. Coll. Med. Genet.
Germ cell numbers in human embryonic and fetal gonads during the first two trimesters of pregnancy: analysis of six published studies
Hum. Reprod. Oxf. Engl.
Menstrual patterns in the first gynecological year: a systematic review
J. Pediatr. Adolesc. Gynecol.
Reproductive ovarian testing and the alphabet soup of diagnoses: DOR, POI, POF, POR, and FOR
J. Assist. Reprod. Genet.
Long-term health consequences of premature or early menopause and considerations for management
Climacteric J. Int. Menopause Soc.
Premature ovarian insufficiency: new perspectives on genetic cause and phenotypic spectrum
Endocr. Rev.
Inheritance in idiopathic premature ovarian failure: analysis of 71 cases
Hum. Reprod. Oxf. Engl.
Identification of the key regulating genes of diminished ovarian reserve (DOR) by network and gene ontology analysis
Mol. Biol. Rep.
Cpipe: a shared variant detection pipeline designed for diagnostic settings
Genome Med.
A deep learning approach for annotating the pathogenicity of genetic variants
Bioinf. Oxf. Engl.
Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces
BMC Bioinf.
BMP15 mutations associated with primary ovarian insufficiency reduce expression, activity, or synergy with GDF9
J. Clin. Endocrinol. Metab.
Immunoneutralization of growth differentiation factor 9 reveals it partially accounts for mouse oocyte mitogenic activity
Biol. Reprod.
Growth differentiation factor 9:bone morphogenetic protein 15 heterodimers are potent regulators of ovarian functions
Proc. Natl. Acad. Sci. U. S. A.
Identification of the first homozygous 1-bp deletion in GDF9 gene leading to primary ovarian insufficiency by using targeted massively parallel sequencing
Clin. Genet.
A homozygous FANCM mutation underlies a familial case of non-syndromic primary ovarian insufficiency
ELife
The nuclear receptor co-repressor nrip1 (RIP140) is essential for female fertility
Nat. Med.
Cited by (40)
Diverse genetic causes of amenorrhea in an ethnically homogeneous cohort and an evolving approach to diagnosis
2024, Molecular and Cellular EndocrinologyUpdate on the genetics and genomics of premature ovarian insufficiency
2023, Human Reproductive and Prenatal GeneticsMelatonin protects against ovarian damage by inhibiting autophagy in granulosa cells in rats
2022, ClinicsCitation Excerpt :Premature Ovarian Insufficiency (POI), also known as premature ovarian failure, is a follicular dysfunction caused by genetic, immune, and environmental factors that seriously affect the endocrine function and fertility of women.1–4
Heterozygosity and homozygosity regions affect reproductive success and the loss of reproduction: A case study with litter traits in pigs
2022, Computational and Structural Biotechnology JournalCitation Excerpt :In addition, the promising candidate genes located across the ROH were associated with embryonic and fetal development. The microtubule actin crosslinking factor 1 (MACF1) gene has been linked to ovarian function [85]. The major facilitator superfamily domain containing 2a (MFSD2A) gene was needed in body growth, lipid metabolism and brain integrity [86].
- 1
Co-senior authors of this study.